Triveni Bio Launches with $92M Series A Financing

Triveni Bio, a biotech company focused on pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of immunological and inflammatory (I&I) disorders, announced a $92 million series A financing co-led by Atlas Venture and Cormorant Asset Management. According to a company press release, the financing will support the advancement of TRIV-509, its lead antibody program, for the treatment of atopic dermatitis, asthma, and other I&I indications.

“We are grateful for the support of our investors who understand the upfront benefit of leveraging human genetics – especially learnings from rare Mendelian forms of disease – to expose novel drug targets relevant across multiple common diseases with shared traits,” said Vishal Patel, PhD, CEO, Triveni Bio. “Triveni Bio is at a key inflection point as we transition into a clinical stage company with a compelling therapeutic pipeline and talented team.”

Reference: Triveni Bio Launches with $92 Million Series A Financing to Advance Genetics-Informed Precision Medicines for the Treatment of Immunological and Inflammatory (I&I) Disorders. PR Newswire. October 26, 2023. Accessed October 26, 2023. https://www.prnewswire.com/news-releases/triveni-bio-launches-with-92-million-series-a-financing-to-advance-genetics-informed-precision-medicines-for-the-treatment-of-immunological-and-inflammatory-ii-disorders-301967602.html